{
    "2021-11-30": [
        [
            {
                "time": "",
                "original_text": "单日8家IPO公司集体大考！多家公司竟携诉讼闯关 诉讼纠纷",
                "features": {
                    "keywords": [
                        "IPO",
                        "诉讼",
                        "纠纷"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "金融",
                        "法律"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "IPO观察｜益方生物零收入闯关，研发费用14亿，专利纠纷缠身",
                "features": {
                    "keywords": [
                        "IPO",
                        "益方生物",
                        "零收入",
                        "研发费用",
                        "专利纠纷"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物科技",
                        "金融"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}